Proteintech acquires nanoantibodies giant ChromeTek.

On October 15th Proteintech Group, a well-known antibody maker, officially announced its wholly-owned acquisition of ChromeTek, a German company.
the latter is a well-known manufacturer of nanoantibodies (also known as alpaca mono-antibodies) dedicated to the development and commercialization of nanoantibodies technology, with a number of the world's leading nanoantibodies technology.
's acquisition expands Proteintech's next-generation antibody tools, further cementing Proteintech's leadership in antibodies, while also better addressing the industry's growing opportunities and challenges in single-cell analysis, ultra-resolution imaging, and multiple analytics, accelerating the implementation of Proteintech's Human Antibody Group Program.
At the same time, the acquisition also means that research users and industrial partners in China and else parts of the country can quickly access ChromeTek's nanoantibodies throughRoteintech's strong sales network, which is a positive driver for the entire biopharmaceutical manufacturing industry and the scientific research sector.
this article is from Bio Valley, for more information please download Bio Valley APP (